Minerva Neurosciences, Inc. (NERV)
2.12
-0.06
(-2.75%)
USD |
NASDAQ |
Nov 19, 16:00
2.13
+0.01
(+0.47%)
After-Hours: 20:00
Minerva Neurosciences Enterprise Value : 100.35M for Nov. 19, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 19, 2026 | 100.35M |
| November 18, 2026 | 103.34M |
| November 17, 2026 | 102.34M |
| November 16, 2026 | 104.33M |
| November 13, 2026 | 109.32M |
| November 12, 2026 | 113.30M |
| November 11, 2026 | 122.27M |
| November 10, 2026 | 118.79M |
| November 09, 2026 | 125.76M |
| November 06, 2026 | 115.30M |
| November 05, 2026 | 109.32M |
| November 04, 2026 | 122.77M |
| November 03, 2026 | 111.81M |
| November 02, 2026 | 111.56M |
| October 30, 2026 | 110.31M |
| October 29, 2026 | 106.33M |
| October 28, 2026 | 104.83M |
| October 27, 2026 | 105.83M |
| October 26, 2026 | 104.33M |
| October 23, 2026 | 109.32M |
| October 22, 2026 | 114.30M |
| October 21, 2026 | 113.80M |
| October 20, 2026 | 120.78M |
| October 19, 2026 | 110.31M |
| October 16, 2026 | 111.81M |
| Date | Value |
|---|---|
| October 15, 2026 | 115.30M |
| October 14, 2026 | 111.81M |
| October 13, 2026 | 120.03M |
| October 12, 2026 | 138.72M |
| October 09, 2026 | 153.17M |
| October 08, 2026 | 155.17M |
| October 07, 2026 | 157.66M |
| October 06, 2026 | 165.63M |
| October 05, 2026 | 160.15M |
| October 02, 2026 | 158.16M |
| October 01, 2026 | 155.66M |
| September 30, 2026 | 161.64M |
| September 29, 2026 | 154.59M |
| September 28, 2026 | 156.95M |
| September 25, 2026 | 156.95M |
| September 24, 2026 | 159.31M |
| September 23, 2026 | 161.20M |
| September 22, 2026 | 176.31M |
| September 21, 2026 | 170.41M |
| September 18, 2026 | 169.23M |
| September 17, 2026 | 159.78M |
| September 16, 2026 | 160.96M |
| September 15, 2026 | 177.25M |
| September 14, 2026 | 185.76M |
| September 11, 2026 | 192.37M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Heron Therapeutics, Inc. | 159.49M |
| Tonix Pharmaceuticals Holding Corp. | -112.71M |
| Karyopharm Therapeutics, Inc. | 191.86M |
| Corbus Pharmaceuticals Holdings, Inc. | -61.25M |
| Ocugen, Inc. | 252.95M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 100.75M |
| Total Expenses (Quarterly) | -100.75M |
| EPS Diluted (Quarterly) | -0.1852 |
| Earnings Yield | -1.35K% |
| Normalized Earnings Yield | -501.61 |